Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG)

Journal of Steroid Biochemistry and Molecular Biology

Volumn 100, Issue 1-3, 2006, Pages 52-58

  Labrie, Fernand ^a   Luu The, Van ^a   Martel, Céline ^a   Chernomoretz, Ariel ^a   Calvo, Ezequiel ^a   Morissette, Jean ^a   Labrie, Claude ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Androgenic anabolic compounds; DHEA; DHT; DNA microarrays; Gene expression profile; Mouse; THG

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANDROSTANOLONE; PRASTERONE; TETRAHYDROGESTRINONE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENOME; GONADECTOMY; MALE; MOLECULAR PROBE; MOUSE; NONHUMAN; ORGAN WEIGHT; PREPUTIAL GLAND; PROSTATE; PROSTATE VENTRAL LOBE; SEMINAL VESICLE;

ANABOLIC AGENTS; ANDROGENS; ANIMALS; ANIMALS, OUTBRED STRAINS; CROSSES, GENETIC; DEHYDROEPIANDROSTERONE; DIHYDROTESTOSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; GENOME; GESTRINONE; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORCHIECTOMY; ORGAN SIZE; PROSTATE; SEMINAL VESICLES; TIME FACTORS;

ANIMALIA;

EID: 33746001106     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.03.006     Document Type: Article

References (37)

1. Labrie F., Luu-The V., Bélanger A., Lin S.-X., Simard J., and Labrie C. Is DHEA a hormone? Starling review. J. Endocrinol. 187 (2005) 169-196
2. Labrie C., Cusan L., Plante M., Lapointe S., and Labrie F. Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem. 28 (1989) 379-384
3. Raynaud J.P., Bonne C., Bouton M.M., Moguilewsky M., Philibert D., and Azadian-Boulanger G. Screening for anti-hormones by receptor studies. J. Steroid Biochem. 6 (1975) 615-622
4. Labrie F., Luu-The V., Lin S.X., Labrie C., Simard J., Breton R., and Bélanger A. The key role of 17β-HSDs in sex steroid biology. Steroids 62 (1997) 148-158
5. Labrie F., Luu-The V., Labrie C., Bélanger A., Simard J., Lin S.-X., and Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24 (2003) 152-182
6. Labrie F., Bélanger A., Candas B., Cusan L., Gomez J.L., Labrie C., Luu-The V., and Simard J. GnRH agonists in the treatment of prostate cancer. Endocr. Rev. 26 (2005) 361-379
7. Labrie F., Luu-The V., Calvo E., Martel C., Cloutier J., Gauthier S., Belleau P., Boucher H., Morissette J., Lévesque M.H., and Labrie C. Tetrahydrogestrinone (THG) induces a genomic signature typical of a potent anabolic steroid. J. Endocrinol. 184 2 (2005) 427-433
8. Kramer C.Y. Extension of multiple range tests to group means with unique numbers of replications. Biometrics 12 (1956) 307-310
9. Vasseur S., Malicet C., Calvo E.L., Labrie C., Berthezene P., Dagorn J.C., and Iovanna J.L. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene. Mol. Cancer 2 (2003) 19
10. R.D.C. Team, A language and environment for statistical computing, R Foundation for Statistical Computing, 2005, ISBN 3-900051-07-0.
11. R.A. Irizarry, L. Gautier, B. Milo Bolstad, C. Miller, M. Astrand, L.M. Cope, R. Gentleman, J. Gentry, W. Huber, B. MacDonald, I.P. Rubenstein, C. Workman, J. Zhang, affy: Methods for Affymetrix Oligonucleotide Arrays, Package Version, 2004, 1.5.8-1.
12. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3 (2004) 3
13. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., Lin L., Chen G., Gharib T.G., Thomas D.G., Lizyness M.L., Kuick R., Hayasaka S., Taylor J.M., Iannettoni M.D., Orringer M.B., and Hanash S. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8 (2002) 816-824
14. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., Jatkoe T., Berns E.M., Atkins D., and Foekens J.A. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (2005) 671-679
15. MacDonald T.J., Brown K.M., LaFleur B., Peterson K., Lawlor C., Chen Y., Packer R.J., Cogen P., and Stephan D.A. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet. 29 (2001) 143-152
16. Korenberg M.J. Gene expression monitoring accurately predicts medulloblastoma positive and negative clinical outcomes. FEBS Lett. 533 (2003) 110-114
17. Dai H., van't Veer L., Lamb J., He Y.D., Mao M., Fine B.M., Bernards R., van de Vijver M., Deutsch P., Sachs A., Stoughton R., and Friend S. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 65 (2005) 4059-4066
18. Pawitan Y., Michiels S., Koscielny S., Gusnanto A., and Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21 (2005) 3017-3024
19. Bullinger L., Dohner K., Bair E., Frohling S., Schlenk R.F., Tibshirani R., Dohner H., and Pollack J.R. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1605-1616
20. Valk P.J., Verhaak R.G., Beijen M.A., Erpelinck C.A., Barjesteh van Waalwijk van Doorn-Khosrovani S., Boer J.M., Beverloo H.B., Moorhouse M.J., van der Spek P.J., Lowenberg B., and Delwel R. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350 (2004) 1617-1628
21. Burnett A.K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-an adult treater's view. Br. J. Haematol. 118 (2002) 357-364
22. Mistry A.R., Pedersen E.W., Solomon E., and Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev. 17 (2003) 71-97
23. Labrie F., and Intracrinology. Mol. Cell. Endocrinol. 78 (1991) C113-C118
24. Labrie F., Bélanger A., Simard J., Luu-The V., and Labrie C. DHEA and peripheral androgen and estrogen formation: intracrinology. Ann. NY Acad. Sci. 774 (1995) 16-28
25. Labrie F., Simard J., Luu-The V., Bélanger A., Pelletier G., Morel Y., Mebarki F., Sanchez R., Durocher F., Turgeon C., Labrie Y., Rhéaume E., Labrie C., and Lachance Y. The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Hansson V., Levy F.O., and Taskén K. (Eds). Proceedings of the Ernst Schering Research Foundation Workshop on Signal Transduction in Testicular Cells, Suppl. 2 (1996), Springer-Verlag, Berlin 185-218
26. Labrie F., Luu-The V., Lin S.-X., Simard J., Labrie C., El-Alfy M., Pelletier G., and Bélanger A. Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 25 (2000) 1-16
27. Labrie F., Luu-The V., Labrie C., and Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol. 22 (2001) 185-212
28. Luu-The V. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J. Steroid Biochem. Mol. Biol. 76 (2001) 143-151
29. Labrie F., Bélanger A., Cusan L., and Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J. Clin. Endocrinol. Metab. 82 (1997) 2403-2409
30. Simpson E.R., and Davis S.R. Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142 (2001) 4589-4594
31. Labrie F., Dupont A., and Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In: de Vita V.T., Hellman S., and Rosenberg S.A. (Eds). Important Advances in Oncology (1985), J.B. Lippincott, Philadelphia 193-217
32. Labrie C., Bélanger A., and Labrie F. Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 123 (1988) 1412-1417
33. Bélanger B., Bélanger A., Labrie F., Dupont A., Cusan L., and Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J. Steroid Biochem. 32 (1989) 695-698
34. Labrie C., Simard J., Zhao H.F., Bélanger A., Pelletier G., and Labrie F. Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology 124 (1989) 2745-2754
35. Diamond P., Cusan L., Gomez J.L., Bélanger A., and Labrie F. Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J. Endocrinol. 150 (1996) S43-S50
36. Neri R., Monahan M.D., Meyer J.G., Afonso B.A., and Tabachnick I.A. Biological studies of an antiandrogen (SH-714). Eur. J. Pharmacol. 1 (1967) 438-444
37. Ebling F.J., Ebling E., Randall V., and Skinner J. The effects of hypophysectomy and of bovine growth hormone on the responses to testosterone of prostate, preputial, Harderian and lachrymal glands and of brown adipose tissue in the rat. J. Endocrinol. 66 (1975) 401-406